Cantor Fitzgerald reaffirmed their overweight rating on shares of Kura Oncology (NASDAQ:KURA – Free Report) in a report issued on Monday, Benzinga reports.
Several other brokerages have also weighed in on KURA. Wedbush restated an outperform rating and issued a $37.00 price objective on shares of Kura Oncology in a report on Friday, August 9th. Stifel Nicolaus reduced their target price on Kura Oncology from $28.00 to $26.00 and set a buy rating for the company in a report on Friday, August 9th. JMP Securities reiterated a market outperform rating and issued a $32.00 price target on shares of Kura Oncology in a research report on Monday, August 12th. StockNews.com lowered Kura Oncology from a hold rating to a sell rating in a research report on Thursday, August 22nd. Finally, HC Wainwright reiterated a buy rating and issued a $32.00 price target on shares of Kura Oncology in a research report on Monday, August 12th. One analyst has rated the stock with a sell rating and six have issued a buy rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of Moderate Buy and a consensus price target of $30.60.
Check Out Our Latest Research Report on KURA
Kura Oncology Trading Up 0.7 %
Kura Oncology (NASDAQ:KURA – Get Free Report) last announced its quarterly earnings data on Thursday, August 8th. The company reported ($0.59) earnings per share for the quarter, beating the consensus estimate of ($0.63) by $0.04. Kura Oncology’s quarterly revenue was up .0% compared to the same quarter last year. During the same period last year, the business posted ($0.53) earnings per share. On average, equities analysts forecast that Kura Oncology will post -2.45 EPS for the current fiscal year.
Institutional Investors Weigh In On Kura Oncology
Several hedge funds have recently bought and sold shares of KURA. SG Americas Securities LLC purchased a new stake in Kura Oncology in the 1st quarter worth about $110,000. Cape Investment Advisory Inc. purchased a new stake in Kura Oncology in the 4th quarter worth about $176,000. Quarry LP purchased a new stake in Kura Oncology in the 2nd quarter worth about $196,000. Saxon Interests Inc. purchased a new stake in Kura Oncology in the 1st quarter worth about $201,000. Finally, Entropy Technologies LP purchased a new stake in Kura Oncology in the 1st quarter worth about $218,000.
Kura Oncology Company Profile
Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.
Featured Articles
- Five stocks we like better than Kura Oncology
- Health Care Stocks Explained: Why You Might Want to Invest
- Goldilocks CPI Report Leads Market to Sell Off, Lower Lows Ahead
- Canadian Penny Stocks: Can They Make You Rich?
- GameStop: Earnings Won’t Save It, Dilution Points to Trouble
- Stock Market Sectors: What Are They and How Many Are There?
- Dividend Aristocrats or Dividend Kings: Which Is Best for You?
Receive News & Ratings for Kura Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kura Oncology and related companies with MarketBeat.com's FREE daily email newsletter.